Current opinion on the diagnosis and management of non-functioning pituitary adenomas

References

• Ntali G, Wass JA. Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas. Pituitary. 2018;21(2):111–118. PubMed PMID: 29368293.
   PubMed Web of Science ®Google Scholar
• Drummond J, Roncaroli F, Grossman AB, et al. Clinical and Pathological Aspects of Silent Pituitary Adenomas. J Clin Endocrinol Metab. 2019;104(7):2473–2489. PubMed PMID: 30020466; PubMed Central PMCID: PMC6517166.
   PubMed Web of Science ®Google Scholar
• Drange MR, Fram NR, Herman-Bonert V, et al. Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metab. 2000;85(1):168–174. PubMed PMID: 10634382.
   PubMed Web of Science ®Google Scholar
• Raappana A, Koivukangas J, Ebeling T, et al. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab. 2010;95(9):4268–4275. Epub 20100609. PubMed PMID: 20534753.
   PubMed Web of Science ®Google Scholar
• Al-Dahmani K, Mohammad S, Imran F, et al. Sellar Masses: an Epidemiological Study. Can J Neurol Sci. 2016;43(2):291–297. Epub 20151102. PubMed PMID: 26522017.
   PubMed Web of Science ®Google Scholar
• Mercado M, Melgar V, Salame L, et al. Clinically non-functioning pituitary adenomas: pathogenic, diagnostic and therapeutic aspects. Endocrinol Diabetes Nutr. 2017;64(7):384–395. Epub 20170704. PubMed PMID: 28745610.
   PubMed Web of Science ®Google Scholar
• Agustsson TT, Baldvinsdottir T, Jonasson JG, et al. The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur J Endocrinol. 2015;173(5):655–664. PubMed PMID: 26423473.
   PubMed Web of Science ®Google Scholar
• Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377–382. Epub 20090724. PubMed PMID: 19650784.
   PubMed Web of Science ®Google Scholar
• Lloyd RV, Osamura RY, Klèoppel G, et al. World Health Organization., International Agency for Research on Cancer. WHO classification of tumours of endocrine organs. 4th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2017. p. 355.
   Google Scholar
• Yavropoulou MP, Tsoli M, Barkas K, et al. The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs). Endocr Relat Cancer. 2020;27(10):R375–R90. PubMed PMID: 32674070.
   PubMed Web of Science ®Google Scholar
• Pagesy P, Li JY, Kujas M, et al. Apparently silent somatotroph adenomas. Pathol Res Pract. 1991;187(8):950–956. PubMed PMID: 1792191.
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001;357(9254):425–431. PubMed PMID: 11273062.
   PubMed Web of Science ®Google Scholar
• Nielsen EH, Lindholm J, Laurberg P, et al. Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function. Pituitary. 2007;10(1):67–73. Epub 20070314. PubMed PMID: 17356906.
   PubMed Web of Science ®Google Scholar
• Olsson DS, Nilsson AG, Bryngelsson IL, et al. Excess Mortality in Women and Young Adults With Nonfunctioning Pituitary Adenoma: a Swedish Nationwide Study. J Clin Endocrinol Metab. 2015;100(7):2651–2658. Epub 20150506. PubMed PMID: 25946030.
   PubMed Web of Science ®Google Scholar
• Ntali G, Capatina C, Fazal-Sanderson V, et al. Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up. Eur J Endocrinol. 2016;174(2):137–145. Epub 20151106. PubMed PMID: 26546611.
   PubMed Web of Science ®Google Scholar
• Karppinen A, Ritvonen E, Roine R, et al. Health-related quality of life in patients treated for nonfunctioning pituitary adenomas during the years 2000-2010. Clin Endocrinol (Oxf). 2016;84(4):532–539. Epub 20151207. PubMed PMID: 26493182.
   PubMed Web of Science ®Google Scholar
• Capatina C, Christodoulides C, Fernandez A, et al. Current treatment protocols can offer a normal or near-normal quality of life in the majority of patients with non-functioning pituitary adenomas. Clin Endocrinol (Oxf). 2013;78(1):86–93. PubMed PMID: 22640418.
   PubMed Web of Science ®Google Scholar
• Freda PU, Bruce JN, Khandji AG, et al. Presenting Features in 269 Patients With Clinically Nonfunctioning Pituitary Adenomas Enrolled in a Prospective Study. J Endocr Soc. 2020;4(4):bvaa021. Epub 20200218. PubMed PMID: 32258955; PubMed Central PMCID: PMC7101088.
   PubMed Web of Science ®Google Scholar
• Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(4):894–904. PubMed PMID: 21474686; PubMed Central PMCID: PMC5393422.
   PubMed Web of Science ®Google Scholar
• Boguszewski CL, de Castro Musolino NR, Kasuki L. Management of pituitary incidentaloma. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101268. Epub 20190413. PubMed PMID: 31027975.
   PubMed Web of Science ®Google Scholar
• Rizzoli P, Iuliano S, Weizenbaum E, et al. Headache in Patients With Pituitary Lesions: a Longitudinal Cohort Study. Neurosurgery. 2016;78(3):316–323. PubMed PMID: 26485333.
   PubMed Web of Science ®Google Scholar
• Abouaf L, Vighetto A, Lebas M. Neuro-ophthalmologic exploration in non-functioning pituitary adenoma. Ann Endocrinol (Paris). 2015;76(3):210–219. Epub 20150610. PubMed PMID: 26070465.
   PubMed Web of Science ®Google Scholar
• Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: a Review. JAMA. 2017;317(5):516–524. PubMed PMID: 28170483.
   PubMed Web of Science ®Google Scholar
• Wildemberg LE, Glezer A, Bronstein MD, et al. Apoplexy in nonfunctioning pituitary adenomas. Pituitary. 2018;21(2):138–144. PubMed PMID: 29383476.
   PubMed Web of Science ®Google Scholar
• Fernández-Balsells MM, Murad MH, Barwise A, et al. Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2011;96(4):905–912. PubMed PMID: 21474687.
   PubMed Web of Science ®Google Scholar
• Biermasz NR. The burden of disease for pituitary patients. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101309. Epub 20190802. PubMed PMID: 31405752.
   PubMed Web of Science ®Google Scholar
• Joustra SD, Kruijssen E, Verstegen MJ, et al. Determinants of altered sleep-wake rhythmicity in patients treated for nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab. 2014;99(12):4497–4505. PubMed PMID: 25210880.
   PubMed Web of Science ®Google Scholar
• Vieira L, Boguszewski CL, Araújo LA, et al. A review on the diagnosis and treatment of patients with clinically nonfunctioning pituitary adenoma by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2016;60(4):374–390. PubMed PMID: 27533614.
   PubMed Web of Science ®Google Scholar
• Langlois F, Woltjer R, Cetas JS, et al. Silent somatotroph pituitary adenomas: an update. Pituitary. 2018;21(2):194–202. PubMed PMID: 29305680.
   PubMed Web of Science ®Google Scholar
• Mete O, Lopes MB. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol. 2017;28(3):228–243. PubMed PMID: 28766057.
   PubMed Web of Science ®Google Scholar
• Inoshita N, Nishioka H. The 2017 WHO classification of pituitary adenoma: overview and comments. Brain Tumor Pathol. 2018;35(2):51–56. Epub 20180423. PubMed PMID: 29687298.
   PubMed Web of Science ®Google Scholar
• Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017;134(4):521–535. Epub 20170818. PubMed PMID: 28821944.
   PubMed Web of Science ®Google Scholar
• Nishioka H, Inoshita N, Mete O, et al. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocr Pathol. 2015;26(4):349–355. PubMed PMID: 26481628.
   PubMed Web of Science ®Google Scholar
• de Almeida Verdolin A, Lamback EB, Ventura N, et al. Collision sellar lesions: coexistence of pituitary adenoma and Rathke cleft cyst-a single-center experience. Endocrine. 2020;68(1):174–181. Epub 20191204. PubMed PMID: 31802354.
   PubMed Web of Science ®Google Scholar
• Manojlovic-Gacic E, Bollerslev J, Casar-Borota O. Invited Review: pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint. Neuropathol Appl Neurobiol. 2020;46(2):89–110. Epub 20190701. PubMed PMID: 31112312.
   PubMed Web of Science ®Google Scholar
• Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178(1):G1–G24. Epub 20171018. PubMed PMID: 29046323.
   PubMed Web of Science ®Google Scholar
• Kasuki L, Raverot G. Definition and diagnosis of aggressive pituitary tumors. Rev Endocr Metab Disord. 2020;21(2):203–208. PubMed PMID: 31808044.
   PubMed Web of Science ®Google Scholar
• Lamback EB, Guterres A, Barbosa MA, et al. Cyclin A in nonfunctioning pituitary adenomas. Endocrine. 2020;70(2):380–387. Epub 2020/ 07/03. PubMed PMID: 32621052.
   PubMed Web of Science ®Google Scholar
• Ogino LL, Lamback EB, Guterres A, et al. Telomerase expression in clinically non-functioning pituitary adenomas. Endocrine. 2021;72(1):208–215. Epub 20201022. PubMed PMID: 33090306.
   PubMed Web of Science ®Google Scholar
• Øystese KA, Zucknick M, Casar-Borota O, et al. Early postoperative growth in non-functioning pituitary adenomas; A tool to tailor safe follow-up. Endocrine. 2017;57(1):35–45. Epub 20170517. PubMed PMID: 28516382.
   PubMed Web of Science ®Google Scholar
• Raverot G, Vasiljevic A, Jouanneau E. Prognostic factors of regrowth in nonfunctioning pituitary tumors. Pituitary. 2018;21(2):176–182. PubMed PMID: 29288467.
   PubMed Web of Science ®Google Scholar
• Cornelius A, Cortet-Rudelli C, Assaker R, et al. Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol. 2012;22(6):757–764. Epub 20120316. PubMed PMID: 22353248.
   PubMed Web of Science ®Google Scholar
• Trouillas J, Roy P, Sturm N, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013;126(1):123–135. Epub 20130212. PubMed PMID: 23400299.
   PubMed Web of Science ®Google Scholar
• Cazabat L, Dupuy M, Boulin A, et al. Silent, but not unseen: multimicrocystic aspect on T2-weighted MRI in silent corticotroph adenomas. Clin Endocrinol (Oxf). 2014;81(4):566–572. Epub 20140505. PubMed PMID: 24601912.
   PubMed Web of Science ®Google Scholar
• Kasuki L, Antunes X, Coelho MCA, et al. Accuracy of microcystic aspect on T2-weighted MRI for the diagnosis of silent corticotroph adenomas. Clin Endocrinol (Oxf). 2020;92(2):145–149. Epub 20191212. PubMed PMID: 31773787.
   PubMed Web of Science ®Google Scholar
• Briet C, Salenave S, Bonneville JF, et al. Pituitary Apoplexy. Endocr Rev. 2015;36(6):622–645. Epub 2015/ 09/28. PubMed PMID: 26414232.
   PubMed Web of Science ®Google Scholar
• Webb KM, Laurent JJ, Okonkwo DO, et al. Clinical characteristics of silent corticotrophic adenomas and creation of an internet-accessible database to facilitate their multi-institutional study. Neurosurgery. 2003;53(5):1076–1084. discussion 84-5. PubMed PMID: 14580274.
   PubMed Web of Science ®Google Scholar
• Raverot G, Wierinckx A, Jouanneau E, et al. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing’s disease. Eur J Endocrinol. 2010;163(1):35–43. Epub 20100412. PubMed PMID: 20385723.
   PubMed Web of Science ®Google Scholar
• Mete O, Gomez-Hernandez K, Kucharczyk W, et al. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol. 2016;29(2):131–142. Epub 20160108. PubMed PMID: 26743473.
   PubMed Web of Science ®Google Scholar
• Fountas A, Lavrentaki A, and Subramanian A, et al. Recurrence in silent corticotroph adenomas after primary treatment: a systematic review and meta-analysis. J Clin Endocrinol Metab;2018 104 4 1039–1048 . Epub 20181221. PubMed PMID: 30590584. DOI:https://doi.org/10.1210/jc.2018-01956
   Web of Science ®Google Scholar
• Di Ieva A, Davidson JM, Syro LV, et al. Crooke’s cell tumors of the pituitary. Neurosurgery. 2015;76(5):616–622. PubMed PMID: 25635886.
   PubMed Web of Science ®Google Scholar
• Karavitaki N, Ansorge O, Wass JA. Silent corticotroph adenomas. Arq Bras Endocrinol Metabol. 2007;51(8):1314–1318. PubMed PMID: 18209869.
   PubMedGoogle Scholar
• Roncaroli F, Faustini-Fustini M, Mauri F, et al. Crooke’s hyalinization in silent corticotroph adenoma: report of two cases. Endocr Pathol. 2002;13(3):245–249. PubMed PMID: 12446925.
   PubMed Web of Science ®Google Scholar
• Giri D, Roncaroli F, Sinha A, et al. Silent Crooke’s cell corticotroph adenoma of the pituitary gland presenting as delayed puberty. Endocrinol Diabetes Metab Case Rep. 2017;2017. Epub 20170331. PubMed PMID: 28458905; PubMed Central PMCID: PMC5404707. DOI:https://doi.org/10.1530/EDM-16-0153.
   Google Scholar
• Todnem N, Ward A, Segar S, et al. Clinically Silent Adrenocorticotropic Hormone-Positive Crooke Cell Adenoma: case Report and Review of Literature. World Neurosurg. 2018;119:197–200. Epub 20180802. PubMed PMID: 30077745.
   PubMed Web of Science ®Google Scholar
• Korbonits M, Carlsen E. Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Horm Res. 2009;71(Suppl 2):123–130. Epub 20090429. PubMed PMID: 19407508.
   PubMedGoogle Scholar
• Righi A, Faustini-Fustini M, Morandi L, et al. The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3. Endocrine. 2017;56(2):286–297. Epub 20160804. PubMed PMID: 27491554.
   PubMed Web of Science ®Google Scholar
• Daems T, Verhelst J, Michotte A, et al. Modification of hormonal secretion in clinically silent pituitary adenomas. Pituitary. 2009;12(1):80–86. PubMed PMID: 18350381.
   PubMed Web of Science ®Google Scholar
• Salgado LR, Machado MC, Cukiert A, et al. Cushing’s disease arising from a clinically nonfunctioning pituitary adenoma. Endocr Pathol. 2006;17(2):191–199. PubMed PMID: 17159252.
   PubMed Web of Science ®Google Scholar
• Mindermann T, Kovacs K, Wilson CB. Changes in the immunophenotype of recurrent pituitary adenomas. Neurosurgery. 1994;35(1):39–44. PubMed PMID: 7936150.
   PubMed Web of Science ®Google Scholar
• Zoli M, Faustini-Fustini M, Mazzatenta D, et al. ACTH adenomas transforming their clinical expression: report of 5 cases. Neurosurg Focus. 2015;38(2):E15. PubMed PMID: 25639317.
   Web of Science ®Google Scholar
• Erickson D, Scheithauer B, Atkinson J, et al. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxf). 2009;71(1):92–99. Epub 20081218. PubMed PMID: 19170710.
   PubMed Web of Science ®Google Scholar
• Horvath E, Kovacs K, Smyth HS, et al. Silent adenoma subtype 3 of the pituitary–immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol. 2005;29(6):511–524. PubMed PMID: 16316952.
   PubMed Web of Science ®Google Scholar
• Lee EB, Tihan T, Scheithauer BW, et al. Thyroid transcription factor 1 expression in sellar tumors: a histogenetic marker? J Neuropathol Exp Neurol. 2009;68(5):482–488. PubMed PMID: 19525896.
   PubMed Web of Science ®Google Scholar
• Casar-Borota O, Botling J, Granberg D, et al. Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas: markers in the Differential Diagnosis of Neuroendocrine Tumors of the Sellar Region. Am J Surg Pathol. 2017;41(9):1238–1246. PubMed PMID: 28719461.
   PubMed Web of Science ®Google Scholar
• Schittenhelm J, Psaras T, Meyermann R, et al. Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms. Folia Neuropathol. 2010;48(2):75–80. PubMed PMID: 20602288.
   PubMed Web of Science ®Google Scholar
• Manojlovic-Gacic E, Engström BE, Casar-Borota O. Histopathological classification of non-functioning pituitary neuroendocrine tumors. Pituitary. 2018;21(2):119–129. PubMed PMID: 29275530; PubMed Central PMCID: PMC5849671.
   PubMed Web of Science ®Google Scholar
• Lamback EB, CHdA L, Miranda RL, et al. USP8 Somatic Mutations in Cushing’s Disease and Silent Corticotropinomas. J Endocr Soc. 2021;5(Supplement_1):A651–A.
   Google Scholar
• Castellnou S, Vasiljevic A, and Lapras V, et al. SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors. Endocr Connect. 2020;9(3):243–253 . Epub 20200201. PubMed PMID: 32101529; PubMed Central PMCID: PMC7077525. DOI:https://doi.org/10.1530/EC-20-0035
   Web of Science ®Google Scholar
• Neou M, Villa C, Armignacco R, et al. Pangenomic Classification of Pituitary Neuroendocrine Tumors. Cancer Cell. 2020;37(1):123–34.e5. Epub 20191226. PubMed PMID: 31883967.
   PubMed Web of Science ®Google Scholar
• Aran V, Heringer M, da Mata PJ, et al. Identification of mutant K-RAS in pituitary macroadenoma. Pituitary. 2021;24(5):746–753 . Epub 20210505 PubMed PMID: 33954928. DOI:https://doi.org/10.1007/s11102-021-01151-6
   PubMed Web of Science ®Google Scholar
• Cooper O, Ben-Shlomo A, Bonert V, et al. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer. 2010;1(2):80–92. PubMed PMID: 20717480; PubMed Central PMCID: PMC2921667.
   PubMedGoogle Scholar
• Tresoldi AS, Carosi G, Betella N, et al. Clinically Nonfunctioning Pituitary Incidentalomas: characteristics and Natural History. Neuroendocrinology. 2020;110(7–8):595–603. Epub 20190913. PubMed PMID: 31525736.
   PubMed Web of Science ®Google Scholar
• Chanson P, Raverot G, Castinetti F, et al. Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris). 2015;76(3):239–247. Epub 20150610. PubMed PMID: 26072284.
   PubMed Web of Science ®Google Scholar
• Esposito D, Olsson DS, Ragnarsson O, et al. Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. Pituitary. 2019;22(4):422–434. PubMed PMID: 31011999; PubMed Central PMCID: PMC6647426.
   PubMed Web of Science ®Google Scholar
• Casanueva FF, Barkan AL, Buchfelder M, et al. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a Pituitary Society Statement. Pituitary. 2017;20(5):489–498. PubMed PMID: 28884415; PubMed Central PMCID: PMC5606938.
   PubMed Web of Science ®Google Scholar
• Li A, Liu W, Cao P, et al. Endoscopic Versus Microscopic Transsphenoidal Surgery in the Treatment of Pituitary Adenoma: a Systematic Review and Meta-Analysis. World Neurosurg. 2017;101:236–246. Epub 20170116. PubMed PMID: 28104521.
   PubMed Web of Science ®Google Scholar
• Yu SY, Du Q, Yao SY, et al. Outcomes of endoscopic and microscopic transsphenoidal surgery on non-functioning pituitary adenomas: a systematic review and meta-analysis. J Cell Mol Med. 2018;22(3):2023–2027. Epub 20180104. PubMed PMID: 29314715; PubMed Central PMCID: PMC5824383.
   PubMed Web of Science ®Google Scholar
• Murad MH, Fernández-Balsells MM, Barwise A, et al. Outcomes of surgical treatment for nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2010;73(6):777–791. PubMed PMID: 20846296.
   PubMed Web of Science ®Google Scholar
• Penn DL, Burke WT, Laws ER. Management of non-functioning pituitary adenomas: surgery. Pituitary. 2018;21(2):145–153. PubMed PMID: 29280026.
   PubMed Web of Science ®Google Scholar
• Little AS, Kelly DF, White WL, et al. Results of a prospective multicenter controlled study comparing surgical outcomes of microscopic versus fully endoscopic transsphenoidal surgery for nonfunctioning pituitary adenomas: the Transsphenoidal Extent of Resection (TRANSSPHER) Study. J Neurosurg. 2019;132(4):1043–1053. Epub 20190322. PubMed PMID: 30901746.
   PubMed Web of Science ®Google Scholar
• Wolf A, Goncalves S, Salehi F, et al. Quantitative evaluation of headache severity before and after endoscopic transsphenoidal surgery for pituitary adenoma. J Neurosurg. 2016;124(6):1627–1633. Epub 20151023. PubMed PMID: 26495954.
   PubMed Web of Science ®Google Scholar
• Nomikos P, Ladar C, Fahlbusch R, et al. Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas – a study on 721 patients. Acta Neurochir (Wien). 2004;146(1):27–35. Epub 2004/ 01/07. PubMed PMID: 14740262.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang CD, Su ZP, et al. Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology. 2012;96(4):333–342. Epub 20120828. PubMed PMID: 22687984.
   PubMed Web of Science ®Google Scholar
• Cortet-Rudelli C, Bonneville JF, Borson-Chazot F, et al. Post-surgical management of non-functioning pituitary adenoma. Ann Endocrinol (Paris). 2015;76(3):228–238. Epub 20150623. PubMed PMID: 26116412.
   PubMed Web of Science ®Google Scholar
• Minniti G, Flickinger J, Tolu B, et al. Management of nonfunctioning pituitary tumors: radiotherapy. Pituitary. 2018;21(2):154–161. PubMed PMID: 29372392.
   PubMed Web of Science ®Google Scholar
• Lucas JW, Bodach ME, Tumialan LM, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Primary Management of Patients With Nonfunctioning Pituitary Adenomas. Neurosurgery. 2016;79(4):E533–5. PubMed PMID: 27635961.
   PubMed Web of Science ®Google Scholar
• Raverot G, Dantony E, Beauvy J, et al. Risk of Recurrence in Pituitary Neuroendocrine Tumors: a Prospective Study Using a Five-Tiered Classification. J Clin Endocrinol Metab. 2017;102(9):3368–3374. PubMed PMID: 28651368.
   PubMed Web of Science ®Google Scholar
• Kotecha R, Sahgal A, Rubens M, et al. Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion. Neuro Oncol. 2020;22(3):318–332. PubMed PMID: 31790121; PubMed Central PMCID: PMC7058447.
   PubMed Web of Science ®Google Scholar
• Even-Zohar N, Greenman Y. Management of NFAs: medical treatment. Pituitary. 2018;21(2):168–175. PubMed PMID: 29344905.
   PubMed Web of Science ®Google Scholar
• Vieira Neto L, Wildemberg LE, Moraes AB, et al. Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy. Clin Endocrinol (Oxf). 2015;82(5):739–746. Epub 2015/ 01/08. PubMed PMID: 25418156.
   PubMed Web of Science ®Google Scholar
• Greenman Y, Cooper O, Yaish I, et al. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol. 2016;175(1):63–72. Epub 2016/ 05/05. PubMed PMID: 27150495.
   PubMed Web of Science ®Google Scholar
• Steeds R, Stiles C, Sharma V, et al. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Clin Endocrinol (Oxf). 2019;90(5):662–669. Epub 2019/ 02/28. PubMed PMID: 30818417.
   PubMed Web of Science ®Google Scholar
• Cooper O, Greenman Y. Dopamine Agonists for Pituitary Adenomas. Front Endocrinol (Lausanne). 2018;9:469. Epub 20180821. PubMed PMID: 30186234; PubMed Central PMCID: PMC6110840.
   PubMed Web of Science ®Google Scholar
• Vieria Neto L, Wildemberg LE, Colli LM, et al. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas. PLoS One. 2013;8(10):e77406. Epub 2013/ 10/02. PubMed PMID: 24098585; PubMed Central PMCID: PMC3788723.
   PubMed Web of Science ®Google Scholar
• Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol. 2007;1561:65–74. Epub 2007/ 01/16. PubMed PMID: 17218727.
   PubMed Web of Science ®Google Scholar
• Colao A, Di Somma C, Pivonello R, et al. Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer. 2008;15(4):905–915. Epub 20080909. PubMed PMID: 18780796.
   PubMed Web of Science ®Google Scholar
• Lee M, Lupp A, Mendoza N, et al. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. Endocr Relat Cancer. 2015;22(1):111–119. Epub 20141216. PubMed PMID: 25515731.
   PubMed Web of Science ®Google Scholar
• Wildemberg LE, Gadelha MR. Pasireotide for the treatment of acromegaly. Expert Opin Pharmacother. 2016;17(4):579–588. Epub 2016/ 02/17. PubMed PMID: 26808354.
   PubMed Web of Science ®Google Scholar
• Gulde S, Wiedemann T, Schillmaier M, et al. Gender-Specific Efficacy Revealed by Head-to-Head Comparison of Pasireotide and Octreotide in a Representative In Vivo Model of Nonfunctioning Pituitary Tumors. Cancers (Basel). 2021;13(12):3097. Epub 20210621. PubMed PMID: 34205778; PubMed Central PMCID: PMC8235746.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Wildemberg LE, Bronstein MD, et al. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. 2017;20(1):100–108. PubMed PMID: 28176162.
   PubMed Web of Science ®Google Scholar
• Vieira Neto L, Chimelli L, Pereira PJ, et al. The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma. Endocr Pract. 2013;19(6):e145–9. PubMed PMID: 23807517.
   PubMed Web of Science ®Google Scholar
• Halevy C, Whitelaw BC. How effective is temozolomide for treating pituitary tumours and when should it be used? . Pituitary. 2017;20(2):261–266.
   PubMed Web of Science ®Google Scholar
• AlMalki MH, Ahmad MM, Brema I, et al. Contemporary Management of Clinically Non-functioning Pituitary Adenomas: a Clinical Review. Clin Med Insights Endocrinol Diabetes. 2020;13:1179551420932921. Epub 20200624. PubMed PMID: 32636692; PubMed Central PMCID: PMC7318824.
   Web of Science ®Google Scholar
• Komor J, Reubi JC, Christ ER. Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma. Pituitary. 2014;17(3):227–231. PubMed PMID: 23740146.
   PubMed Web of Science ®Google Scholar
• Dai C, Liang S, Sun B, et al. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. Front Endocrinol (Lausanne). 2020;11:608422. Epub 20201211. PubMed PMID: 33362722; PubMed Central PMCID: PMC7761748.
   PubMed Web of Science ®Google Scholar
• Wang Z, Guo X, Gao L, et al. The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness. J Clin Endocrinol Metab. 2020;105(9):e3207–e3223. PubMed PMID: 32652004; PubMed Central PMCID: PMC7413599.
   PubMed Web of Science ®Google Scholar
• Di Nunno V, Franceschi E, Tosoni A, et al. Immune-checkpoint inhibitors in pituitary malignancies. Anticancer Drugs. 2021;Publish Ahead of Print. Epub 20210803. PubMed PMID: 34348358. DOI:https://doi.org/10.1097/CAD.0000000000001157.
   Google Scholar
• Keil MF, Stratakis CA. Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev Neurother. 2008;8(4):563–574. PubMed PMID: 18416659; PubMed Central PMCID: PMC2743125.
   PubMedGoogle Scholar
• Guaraldi F, Storr HL, Ghizzoni L, et al. Paediatric pituitary adenomas: a decade of change. Horm Res Paediatr. 2014;81(3):145–155. Epub 20140211. PubMed PMID: 24525527.
   PubMed Web of Science ®Google Scholar
• Pandey P, Ojha BK, Mahapatra AK. Pediatric pituitary adenoma: a series of 42 patients. J Clin Neurosci. 2005;12(2):124–127. PubMed PMID: 15749410.
   PubMed Web of Science ®Google Scholar
• Perry A, Graffeo CS, Marcellino C, et al. Pediatric Pituitary Adenoma: case Series, Review of the Literature, and a Skull Base Treatment Paradigm. J Neurol Surg B Skull Base. 2018;79(1):91–114. Epub 20180124. PubMed PMID: 29404245; PubMed Central PMCID: PMC5796823.
   PubMed Web of Science ®Google Scholar
• Walz PC, Drapeau A, Shaikhouni A, et al. Pediatric pituitary adenomas. Childs Nerv Syst. 2019;35(11):2107–2118. Epub 20190713. PubMed PMID: 31302729.
   PubMed Web of Science ®Google Scholar
• Srirangam Nadhamuni V, Korbonits M. Novel Insights into Pituitary Tumorigenesis: genetic and Epigenetic Mechanisms. Endocr Rev. 2020;41(6). PubMed PMID: 32201880; PubMed Central PMCID: PMC7441741. DOI:https://doi.org/10.1210/endrev/bnaa006.
   Google Scholar
• O’Toole SM, Dénes J, Robledo M, et al. 15 YEARS OF PARAGANGLIOMA: the association of pituitary adenomas and phaeochromocytomas or paragangliomas. Endocr Relat Cancer. 2015;22(4):T105–22. Epub 20150625. PubMed PMID: 26113600.
   PubMed Web of Science ®Google Scholar
• Marques P, Caimari F, Hernández-Ramírez LC, et al. Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors. J Clin Endocrinol Metab. 2020;105(6):e2247–e2260. PubMed PMID: 31996917; PubMed Central PMCID: PMC7137887.
   Web of Science ®Google Scholar
• Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386(1–2):2–15. Epub 2013/ 08/08. PubMed PMID: 23933118; PubMed Central PMCID: PMC4082531.
   PubMed Web of Science ®Google Scholar
• Stratakis CA, Schussheim DH, Freedman SM, et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2000;85(12):4776–4780. PubMed PMID: 11134142.
   PubMed Web of Science ®Google Scholar